MAZE vs ACMR

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). ACM Research, Inc. (ACMR) offers the better valuation at 66. 9x trailing P/E (46. 0x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +209. 9%, compared to +51. 0% for Maze Therapeutics, Inc. (MAZE). Over 10 years, the gap is even starker: ACMR returned +48. 0% versus MAZE's +51. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Maze Therapeutics, Inc.

(MAZE) is the lower-risk stock at 1. 13β versus ACM Research, Inc. 's 3. 40β — meaning ACMR is approximately 201% more volatile than MAZE relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 16% for ACM Research, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: ACM Research, Inc. grew EPS -10. 5% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MAZE: 162.

6% to $63. 25.

In this comparison, ACMR (0.

1% yield) pays a dividend. MAZE does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Maze Therapeutics, Inc.

(MAZE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MAZE: +51. 0%, ACMR: +48. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MAZE (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAZE is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.